Screener
Enovis ENOV Other Prevention and Recovery — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enovis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Enovis’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001420800-26-000035
| Line item | Three Months Ended / July 3, 2026 | Three Months Ended / July 4, 2025 | Six Months Ended / July 3, 2026 | Six Months Ended / July 4, 2025 |
|---|---|---|---|---|
| Prevention & Recovery: | ||||
| U.S. Bracing & Support | $127,610 | $120,850 | $242,493 | $235,936 |
| U.S. Other P&R (1) | 59,637 | 70,823 | 115,499 | 137,445 |
| International P&R | 101,001 | 98,897 | 202,274 | 189,773 |
| Total Prevention & Recovery | 288,248 | 290,570 | 560,266 | 563,154 |
| Reconstructive: | ||||
| U.S. Recon | 137,829 | 129,493 | 287,037 | 267,370 |
| International Recon | 156,705 | 144,482 | 324,630 | 292,855 |
Item 1. Financial Statements
FAQ
- What is Enovis's other prevention and recovery — net sales?
- Enovis (ENOV) reported other prevention and recovery — net sales of $59.64M in Q2 2026.
- How has Enovis's other prevention and recovery — net sales changed year-over-year?
- Enovis's other prevention and recovery — net sales decreased by 15.8% year-over-year, from $70.82M to $59.64M.
- What is the long-term trend for Enovis's other prevention and recovery — net sales?
- Over 4 years (2021 to 2025), Enovis's other prevention and recovery — net sales has grown at a 2.8% compound annual growth rate (CAGR), from $243.05M to $271.64M.
- What does other prevention and recovery — net sales mean?
- This metric represents the total revenue generated from the sale of goods and services within the specialized Prevention and Recovery segment, excluding any assessed taxes. It reflects the market demand and commercial performance of medical devices and solutions focused on patient rehabilitation, pain management, and physical therapy. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of the company's non-reconstructive medical technology portfolio.
Ask your AI about Enovis's other prevention and recovery — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude